Evidence map›Paper›PMID 36657243›Full record

SynthesisJournal of infection and public health2023

Impact of COVID-19 pandemic on multidrug resistant gram positive and gram negative pathogens: A systematic review.

Usman Abubakar, Menier Al-Anazi, Zainab Alanazi, Jesús Rodríguez-Baño

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Journal of infection and public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 1 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. The global epidemiology of MRSA.JAC-antimicrobial resistance · 2026
    Review
  8. Article
  9. Article
  10. Observational
  11. Multidrug-resistant Pseudomonas aeruginosa in ICU patients and hospital surfaces: β-lactamase burden, biofilm formation and clonal spread.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  12. Article
  13. A Seven-Year Study of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026
    Article
  14. Review
  15. Trends, Seasonality, and the Impact of COVID-19 on ClinicalAntibiotics (Basel, Switzerland) · 2026
    Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 3 countries.

Usman AbubakarDiscipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Penang, Malaysia. Electronic address: pharmumma2@gmail.com.
Menier Al-AnaziFaculty of Science, University of Tabuk, Tabuk 71491, Kingdom of Saudi Arabia.
Zainab AlanaziDepartment of Family Medicine, King Salman Armed Forces Hospital, Tabuk 47512, Saudi Arabia.
Jesús Rodríguez-BañoBiomedicine Institute of Seville (IBiS)/CSIC, Seville, Spain. CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain; Department of Medicine, University of Seville, Madrid, Spain; Infectious Diseases and Microbiology division, Hospital Universitario Virgen Macarena, Seville, Spain. CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
Armed Forces Hospital · SAInstituto de Salud Carlos III · ESUniversiti Sains Malaysia · MYUniversity of Tabuk · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is paucity of data describing the impact of COVID-19 pandemic on antimicrobial resistance. This review evaluated the changes in the rate of multidrug resistant gram negative and gram positive bacteria during the COVID-19 pandemic.

methodsA search was conducted in PubMed, Science Direct, and Google Scholar databases to identify eligible studies. Studies that reported the impact of COVID-19 pandemic on carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta-lactamase inhibitor (ESBL)-producing Enterobacteriaceae, vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Pseudomonas aeruginosa (CPE) were selected. Studies published in English language from the start of COVID-19 pandemic to July 2022 were considered for inclusion.

resultsThirty eligible studies were selected and most of them were from Italy (n = 8), Turkey (n = 3) and Brazil (n = 3). The results indicated changes in the rate of multidrug resistant bacteria, and the changes varied between the studies. Most studies (54.5%) reported increase in MRSA infection/colonization during the pandemic, and the increase ranged from 4.6 to 170.6%. Five studies (55.6%) reported a 6.8-65.1% increase in VRE infection/colonization during the pandemic. A 2.4-58.2% decrease in ESBL E. coli and a 1.8-13.3% reduction in ESBL Klebsiella pneumoniae was observed during the pandemic. For CRAB, most studies (58.3%) reported 1.5-621.6% increase in infection/colonization during the pandemic. Overall, studies showed increase in the rate of CRE infection/colonization during the pandemic. There was a reduction in carbapenem-resistant E. coli during COVID-19 pandemic, and an increase in carbapenem-resistant K. pneumoniae. Most studies (55.6%) showed 10.4 - 40.9% reduction in the rate of CRPA infection during the pandemic.

conclusionThere is an increase in the rate of multidrug resistant gram positive and gram negative bacteria during the COVID-19 pandemic. However, the rate of ESBL-producing Enterobacteriaceae and CRPA has decrease during the pandemic. Both infection prevention and control strategies and antimicrobial stewardship should be strengthen to address the increasing rate of multidrug resistant gram positive and gram negative bacteria.

Indexed as

COVID-19Methicillin-Resistant Staphylococcus aureusAnti-Bacterial AgentsCarbapenemsEnterobacteriaceaeEscherichia coliGram-Negative BacteriaGram-Positive BacteriaHumansKlebsiella pneumoniaeMicrobial Sensitivity TestsPandemicsAnti-Bacterial AgentsCarbapenemsAntimicrobial resistanceCarbapenem-resistant enterobacteriaceaeCOVID-19 pandemicGram negativeGram positiveImpactMRSAVancomycin-resistant enterococci

Identifiers

PMID36657243
PMCPMC9804969
OpenAlexW4313398346

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.